Hereditary Angioedema
Hereditary angioedema attacks fall nearly 95% with lanadelumab among adolescents
Adolescents with hereditary angioedema experienced fewer attacks, improved quality of life and treatment satisfaction with lanadelumab, according to a study published in Annals of Allergy, Asthma & Immunology.
Bridging the Health Gaps in Hereditary Angioedema: Demystifying Disparities, Enhancing Quality of Life, and Implementing Effective Prophylactic Solutions
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Top news of July: Anaphylaxis guidelines, epinephrine, FDA applications, more
Healio has compiled July’s most-read news in asthma and allergy.
Top in allergy/asthma: Modified anaphylaxis criteria; oral immunotherapy for children
A recent study found that health care professionals were increasingly able to identify infants and young children with anaphylaxis by following modified criteria.
KalVista Pharmaceuticals submits FDA application for sebetralstat
KalVista Pharmaceuticals Inc. submitted a new drug application to the FDA for the approval of sebetralstat for patients aged 12 years and older with hereditary angioedema, according to a company press release.
Donidalorsen may reduce hereditary angioedema attack rates
Donidalorsen trials showed positive results in treating patients with hereditary angioedema, exhibiting significant reductions in attack rates, according to a study published in The New England Journal of Medicine.
Patients with hereditary angioedema visit the hospital less often with berotralstat
Patients with hereditary angioedema experienced fewer hospitalizations and ED and outpatient visits after beginning prophylactic treatment with berotralstat, according to a poster presented at a recent conference.
MicroRNAs may be biomarkers in hereditary angioedema
MicroRNAs may indicate patients who have hereditary angioedema along with different phenotypes of the disease, according to a study published in Annals of Allergy, Asthma & Immunology.
Deep quantum modeling enables new drugs for hereditary angioedema
With deep quantum modeling, researchers can go beyond the millions of distinct chemical structures previously accessible to scientists and explore 1060 possible combinations to find treatments for hereditary angioedema and other diseases.
Hereditary angioedema attacks fall by 80% with lanadelumab
WASHINGTON — Patients with hereditary angioedema experienced reductions in the monthly rate of attacks with lanadelumab, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.